Belite Bio (NASDAQ:BLTE) Raised to “Hold” at Wall Street Zen

Belite Bio (NASDAQ:BLTE) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other research analysts have also commented on the company. Needham & Company LLC set a $217.00 price target on Belite Bio in a report on Tuesday, March 3rd. Bank of America initiated coverage on shares of Belite Bio in a research report on Monday, January 26th. They issued a “buy” rating and a $195.00 target price for the company. Mizuho set a $223.00 target price on shares of Belite Bio in a research note on Thursday, February 19th. Cantor Fitzgerald upped their price target on shares of Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Finally, Maxim Group set a $200.00 price objective on shares of Belite Bio in a report on Tuesday, December 2nd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Belite Bio presently has an average rating of “Moderate Buy” and an average price target of $202.33.

Belite Bio Trading Up 0.4%

Shares of NASDAQ BLTE opened at $173.30 on Friday. Belite Bio has a 12-month low of $49.00 and a 12-month high of $200.00. The company has a market cap of $6.82 billion, a PE ratio of -75.35 and a beta of -1.46. The stock has a 50 day simple moving average of $170.11 and a 200-day simple moving average of $125.65.

Belite Bio (NASDAQ:BLTE) last announced its earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.18. Sell-side analysts forecast that Belite Bio will post -1.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BLTE. Caitong International Asset Management Co. Ltd increased its holdings in shares of Belite Bio by 28,200.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock valued at $45,000 after buying an additional 282 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Belite Bio in the 4th quarter worth $103,000. Persistent Asset Partners Ltd acquired a new position in shares of Belite Bio in the 4th quarter worth $108,000. Bank of America Corp DE raised its position in shares of Belite Bio by 28.1% during the third quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock worth $87,000 after purchasing an additional 257 shares during the period. Finally, Independent Advisor Alliance acquired a new stake in shares of Belite Bio during the fourth quarter worth $211,000. Institutional investors and hedge funds own 0.53% of the company’s stock.

More Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Cantor Fitzgerald published a bullish outlook that analysts say supports upside potential for BLTE shares; this contributed to positive investor sentiment today. Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says
• Positive Sentiment: Morgan Stanley is also cited as forecasting strong price appreciation for Belite Bio, helping lift the stock as momentum and analyst optimism draw buyer interest. Morgan Stanley Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Positive Sentiment: An American Banking News item highlights HC Wainwright’s continued bullish stance (Buy, $200 target), which can limit downside even as estimates shift. HC Wainwright Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Neutral Sentiment: Reported short?interest figures appear to show zero shares and a 0.0 days?to?cover ratio — likely a data anomaly or reporting issue rather than meaningful new short activity. That makes the short?interest data neutral for near?term price direction.
• Negative Sentiment: HC Wainwright reduced its near?term EPS forecasts in a March 3 research note: Q1 2026 EPS cut from ($0.56) to ($0.71), Q2 from ($0.56) to ($0.72), Q3 from ($0.57) to ($0.73), Q4 2026 from $5.80 to $4.05, and FY2026 from $4.12 to $1.89. Although the firm kept a Buy rating and $200 target, the sizable downward revisions to quarterly and full?year earnings increase uncertainty around near?term results and could pressure the stock if upcoming operational or clinical updates fall short. Belite Bio (BLTE) MarketBeat company page

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.